Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002011531 | SCV002303241 | uncertain significance | TP63-Related Spectrum Disorders | 2023-08-11 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 21 of the TP63 protein (p.Arg21His). This variant also falls at the last nucleotide of exon 1, which is part of the consensus splice site for this exon. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 1510128). This variant has not been reported in the literature in individuals affected with TP63-related conditions. This variant is present in population databases (rs766583971, gnomAD 0.006%). |
Fulgent Genetics, |
RCV002479771 | SCV002781266 | uncertain significance | ADULT syndrome; Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome; Ectrodactyly, ectodermal dysplasia, and cleft lip-palate syndrome 3; Limb-mammary syndrome; Rapp-Hodgkin syndrome; Split hand-foot malformation 4; Orofacial cleft 8 | 2022-05-05 | criteria provided, single submitter | clinical testing | |
Clinical Genetics Laboratory, |
RCV004697185 | SCV005198849 | uncertain significance | not provided | 2023-10-10 | criteria provided, single submitter | clinical testing |